Asthma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For healthy volunteers:
- Adults aged 18 to 70 years (male or female)
- People who are able to give written consent and follow the study requirements
- People whose airways do not show unusual sensitivity to a breathing test substance called methacholine (at a level above 16 mg/mL)
- People with no history of allergic rhinitis or seasonal allergies
For people with asthma:
- Adults aged 18 to 70 years (male or female)
- People who are able to give written consent and follow the study requirements
- People with a diagnosed history of asthma
- People who have not used oral or inhaled corticosteroids (steroid medications) for asthma in the past 6 weeks
- People whose airways show sensitivity to methacholine in a breathing test (at a level below 8 mg/mL)
Who may not be able to join:
- People who currently smoke more than 5 cigarettes in the past 12 months and smoked within the last 8 weeks, or former smokers with a total smoking history of 10 or more pack-years (a measure of long-term smoking history — confirm with trial site)
- People who are pregnant, breastfeeding, or unwilling to use birth control during the study
- People with a history of lung disease other than asthma
- People who have previously had surgery for an oesophageal hernia
- People with other medical conditions that, in the doctor's opinion, could put them at extra risk or affect the study results
- People currently taking part in another clinical drug trial
- People currently taking certain medications that must be stopped before joining, including:
- Astemizole (an antihistamine) within the past 12 weeks
- Steroid medications — oral, inhaled, or nasal — within the past 6 weeks
- Nedocromil sodium or sodium cromoglycate within the past 4 weeks
- Long-acting methylxanthines (a type of airway-opening medication) within the past 2 days
- Short-acting methylxanthines within the past 12 hours
- Montelukast or zafirlukast (asthma controller medications) within the past 7 days
- Salmeterol (a long-acting inhaler medication) within the past 2 days
- Omalizumab (a biological asthma medication) within the past 6 months
- People who have taken aspirin or anti-inflammatory medications (such as ibuprofen) within 2 days before a bronchoscopy procedure
- People who have taken short-acting inhalers, certain anticholinergic medications, or antihistamines within specified hours before each clinic visit (confirm exact timeframes with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Nirav Bhakta, MD, PhD, University of California, San Francisco
Phone: 628-233-1233
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Quantitate mean gene expression of TSPAN8 in goblet cells from the airways of human asthma and health and report the mean for asthma and health (main outcome 1) and for both goblet cells and non-goblet cells in asthma.; Quantitate KRT8 in airway cells from human asthma vs health and report the mean level in the transitional secretory cell subset for both asthma and health.; Quantitate expression of miR-141/200 family members report mean expression for the transitional secretory cell population in human asthma vs health using methods similar to those in Outcomes 1 and 2.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.